Lymphomas are the most common hematologic malignancies ... Additionally, we briefly discuss the prognostic significance of select biological markers.

The trials generated proof-of-concept clinical data in AML, lymphoma and pancreatic cancer. Marker is rapidly advancing its multiTAA therapies through phase 1 and 2 proof-of-concept trials ...

A doctor can use biopsies to look for an accumulation of lymphoma cells in blood vessels. Testing called immunohistochemistry can be done on biopsy samples to look for cellular markers associated ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma ...

PROGRAM UPDATES & EXPECTED MILESTONES MT-601 (Lymphoma) Marker’s lead program is investigating MT-601 in the nationwide multicenter Phase 1 APOLLO study (clinicaltrials.gov identifier ...